Bristol Myers Squibb Company BMY

62.86 1.36 2.21% as of 25 Sep
Market cap
$125.9B
P/E
13.8×
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years

Bristol Myers Squibb Company (BMY) Free cash flow margin

Bristol Myers Squibb Company's free cash flow margin over the twelve months to 30 June 2026 was 23.3%, down 3.4 percentage points from fiscal 2025 (26.7%). Over the past ten years it has ranged from 7.76% (fiscal 2015) to 32.8% (fiscal 2021); the current reading is higher than 45% of that period. That is above the Drug Manufacturers General industry median of 17.3% and above the Healthcare sector median of 0.00%.

Free cash flow margin, annual

Annual

Period Free cash flow margin Change (points)
FY2025 26.7% (2.22)
FY2024 28.9% 0.76
FY2023 28.1% 2.23
FY2022 25.9% (6.96)
FY2021 32.8% 1.56
FY2020 31.3% 3.08
FY2019 28.2% 1.10
FY2018 27.1% 6.79
FY2017 20.3% 10.82
FY2016 9.49% 1.73

Against its own ten years

Low 7.76% High 32.8%
Ten-year median 27.1%
Current reading's percentile 45

Free cash flow margin against peers

Company Free cash flow margin
GILD Gilead Sciences, Inc. compare 42.5%
NVS Novartis AG compare 26.8%
AMGN Amgen Inc. compare 26.7%
SNY Sanofi compare 25.5%
BMY Bristol Myers Squibb Company 23.3%
PFE Pfizer Inc. compare 17.3%
GSK GSK PLC Sponsored ADR compare 17.2%
NVO Novo Nordisk A/S compare 14.8%
AZN AstraZeneca PLC compare 10.2%
Drug Manufacturers General industry median 17.3%
Healthcare sector median 0.00%
Market median 0.00%

What Free cash flow margin is

Free Cash Flow Margin tells an investor how much of each sale turns into cash the company keeps after paying for investment in its assets.

(Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)) ÷ Revenue

The full definition of Free cash flow margin →

More on BMY